Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | BeOne Medicines

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Beigene Study ID

BGB-3111-207

ClinicalTrials.gov ID

NCT03145064

China Drug Trials ID

CTR20170091

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan